3/9/26 19:03 | 3/9/26 | MYGN | Myriad Genetics Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Raha Samraat S. | UT | DO | P,CEO | 1 | P | 200 | 5.00 | 0 | 40 | 9 | 493 | D | | | | | | | | | | | | | | |
3/9/26 16:30 | 3/6/26 | TKNO | Alpha Teknova, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Lowell Matthew | CA | O | CFO | 1 | P.d | 88 | 2.19 | 0 | 40 | 31 | 168 | D | | | | | | | | | | | | | | |
3/9/26 16:24 | 3/6/26 | TKNO | Alpha Teknova, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Gunstream Stephen | CA | DO | P,CEO | 1 | P.d | 56 | 2.15 | 0 | 26 | 11 | 269 | D | | | | | | | | | | | | | | |
3/5/26 17:01 | 3/3/26 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Underberg Sharon E. | ME | O | EVP,GC,C | 2 | M.d | 100 | 96.78 | 0 | 1 | 17 | 7 | D | | | | | | | | | | | | | | |
3/5/26 17:01 | 3/3/26 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Hunt Nimrata | ME | O | EVP | 3 | S.d | -2,897 | 411.64 | 0 | -7 | | 23 | D | | | | | | | | | | | | | | |
3/3/26 16:16 | 3/2/26 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Clark Eliana | MA | O | EVP,Chie | 2 | S.d | -96 | 9.48 | 0 | -10 | | 94 | D | | | | | | | | | | | | | | |
3/2/26 17:00 | 2/26/26 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Mazelsky Jonathan Jay | ME | DO | P,CEO | 3 | M.dm | 18,741 | 383.20 | 0 | 49 | 140 | 84 | D | | | | | | | | | | | | | | |
3/2/26 17:00 | 2/26/26 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Mazelsky Jonathan Jay | ME | DO | P,CEO | 3 | S.dm | -18,741 | 383.20 | 0 | -49 | | 84 | D | | | | | | | | | | | | | | |
2/27/26 16:46 | 2/25/26 | MYGN | Myriad Genetics Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Phanstiel S. Louise | UT | D | | 1 | P.m | 495 | 4.73 | 0 | 105 | 50 | 315 | D | | | | | | | | | | | | | | |
2/19/26 18:00 | 2/17/26 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Erickson Michael G | ME | O | EVP | 3 | M.dm | 4,830 | 311.53 | 0 | 16 | | 15 | D | | | | | | | | | | | | | | |
2/19/26 18:00 | 2/17/26 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Erickson Michael G | ME | O | EVP | 3 | S.dm | -4,830 | 311.53 | 0 | -16 | | 15 | D | | | | | | | | | | | | | | |
2/19/26 18:00 | 2/17/26 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Vandebroek Sophie V. | ME | D | | 2 | M.d | 1,236 | 513.01 | 0 | 2 | 38 | 9 | D | | | | | | | | | | | | | | |
2/19/26 18:00 | 2/17/26 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Vandebroek Sophie V. | ME | D | | 2 | S.d | -1,236 | 513.01 | 0 | -2 | | 9 | D | | | | | | | | | | | | | | |
2/19/26 16:18 | 2/13/26 | QDEL | Quidelortho Corp | | Health | Diagn | In Vitro & In Vivo Diagnostic | Busky Joseph M. | CA | O | CFO | 2 | P | 159 | 23.66 | 0 | 7 | 15 | 52 | I | | | | | | | | | | | | | | |
2/17/26 19:31 | 2/14/26 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Smith Martin Alexander | ME | O | EVP | 1 | M.d | 0 | 0.00 | 0 | 1 | 87 | 2 | D | | | | | | | | | | | | | | |
2/17/26 19:31 | 2/14/26 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Schreck Michael | ME | O | EVP | 1 | M.d | 0 | 0.00 | 0 | 2 | 173 | 3 | D | | | | | | | | | | | | | | |
2/17/26 19:30 | 2/14/26 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Lane Michael | ME | O | EVP | 1 | M.d | 0 | 0.00 | 0 | 1 | 15 | 9 | D | | | | | | | | | | | | | | |
2/17/26 19:30 | 2/14/26 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Johnson Michael Perkins | ME | O | EVP | 1 | M.d | 0 | 0.00 | 0 | 1 | 26 | 3 | D | | | | | | | | | | | | | | |
2/17/26 19:30 | 2/14/26 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Fennell George | ME | O | EVP | 3 | M.dm | 8,207 | 333.34 | 0 | 25 | | 10 | D | | | | | | | | | | | | | | |
2/17/26 19:30 | 2/14/26 | IDXX | Idexx Laboratories Inc /De | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Emerson Andrew | ME | O | EVP,CFO, | 1 | M.d | 0 | 0.00 | 0 | 0 | 12 | 4 | D | | | | | | | | | | | | | | |
2/17/26 15:12 | 2/17/26 | NEOG | Neogen Corp | MI | Health | Diagn | In Vitro & In Vivo Diagnostic | Nassif Mikheal | MI | DO | CEO | 3 | P.m | 2 | 9.65 | 0 | 0 | 42 | 1 | I | | | | | | | | | | | | | | |
2/13/26 16:20 | 2/13/26 | QDEL | Quidelortho Corp | | Health | Diagn | In Vitro & In Vivo Diagnostic | Strobeck Matthew | CA | D | | 1 | P | 240 | 23.96 | 0 | 10 | 14 | 83 | D | | | | | | | | | | | | | | |
2/13/26 10:43 | 2/13/26 | QDEL | Quidelortho Corp | | Health | Diagn | In Vitro & In Vivo Diagnostic | Blaser Brian J. | CA | O | P,CEO | 1 | P | 249 | 23.59 | 0 | 11 | 19 | 65 | I | | | | | | | | | | | | | | |
2/12/26 19:49 | 2/10/26 | IMDX | Insight Molecular Diagnostics Inc. | CA | Health | Diagn | In Vitro & In Vivo Diagnostic | Broadwood Partners, L.P. | NY | T | | 1 | P.d | 3,000 | 5.75 | 0 | 522 | 2 | 23,864 | M | | | | | | | | | | | | | | |
2/2/26 20:51 | 1/30/26 | IONS | Ionis Pharmaceuticals Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Hougen Elizabeth L | CA | O | EVP,Fina | 3 | S.d | -1,554 | 31.94 | 0 | -49 | | 133 | D | | | | | | | | | | | | | | |
1/7/26 16:05 | 1/5/26 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Leonard John M | MA | DO | P,CEO | 1 | S | -314 | 9.21 | 0 | -34 | | 1,072 | D | | | | | | | | | | | | | | |
1/7/26 16:05 | 1/5/26 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Schultes Birgit C | MA | O | EVP,Chie | 1 | S | -78 | 9.21 | 0 | -9 | | 99 | D | | | | | | | | | | | | | | |
1/7/26 16:05 | 1/5/26 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Basta James | MA | O | EVP,GC | 1 | S | -96 | 9.21 | 0 | -10 | | 102 | D | | | | | | | | | | | | | | |
1/7/26 16:05 | 1/5/26 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Cohen Fred E | MA | D | | 1 | P | 1,403 | 9.35 | 0 | 150 | 261 | 207 | D | | | | | | | | | | | | | | |
1/7/26 16:04 | 1/5/26 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Lebwohl David | MA | O | EVP,Chie | 1 | S | -110 | 9.21 | 0 | -12 | | 121 | D | | | | | | | | | | | | | | |
1/7/26 16:02 | 1/5/26 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Dulac Edward J III | MA | O | EVP,CFO | 1 | S | -59 | 9.21 | 0 | -6 | | 100 | D | | | | | | | | | | | | | | |
1/7/26 16:01 | 1/5/26 | NTLA | Intellia Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Dube Michael P | MA | O | VP,Chief | 1 | S | -28 | 9.21 | 0 | -3 | | 52 | D | | | | | | | | | | | | | | |
1/6/26 16:23 | 1/2/26 | CLDX | Celldex Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Martin Samuel Bates | NJ | O | SVP,CFO | 1 | M.d | 50 | 10.38 | 0 | 5 | 17 | 33 | D | | | | | | | | | | | | | | |
12/17/25 16:06 | 12/15/25 | CLDX | Celldex Therapeutics, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Pepin Ronald | NJ | O | SVP,CBO | 1 | M.d | 106 | 5.47 | 0 | 19 | 999% | 20 | D | | | | | | | | | | | | | | |